Nektar Up 3% Since 10 a.m. Release On Presentation Of Preclinical Comments For NKTR-181 This Week; Mizuho Analyst, Asked If Release Could Have Moved Stock, Said 'NKTR-181 accounts for $2-3/share in my valuation, so I don't think it can move the stock'
Benzinga Newsdesk